oncology innovation 2025

Imagine an oncologist stepping out of tumor board and into clinic with a complex case at hand. The patient’s tumor has multiple high-risk features, genomic mutations, and borderline indications for therapy. In the past, the doctor might sift through guidelines,…

I grew up around a lot of physicians,” begins Adrian Gottschalk, President and CEO of Foghorn Therapeutics, a biotech company redefining how we understand and treat complex diseases by targeting the chromatin regulatory system. “My late father was a professor…